Current prognostic tools, such as pre-operative prostate specific antigen (PSA) levels, histological Gleason grading, clinical tumor, node, and metastasis (TNM) staging are used to place men in low-, intermediate-, and high-risk prostate cancer risk groupings. This evidence concerns the gene KLK3 and prostate cancer.